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Introduction: The Network Genomic Medicine Lung Cancer was 
set up to rapidly translate scientific advances into early clinical trials 
of targeted therapies in lung cancer performing molecular analyses of 
more than 3500 patients annually. Because sequential analysis of the 
relevant driver mutations on fixated samples is challenging in terms 
of workload, tissue availability, and cost, we established multiplex 
parallel sequencing in routine diagnostics. The aim was to analyze all 
therapeutically relevant mutations in lung cancer samples in a high-
throughput fashion while significantly reducing turnaround time and 
amount of input DNA compared with conventional dideoxy sequenc-
ing of single polymerase chain reaction amplicons.
Methods: In this study, we demonstrate the feasibility of a 102 ampli-
con multiplex polymerase chain reaction followed by sequencing on 
an Illumina sequencer on formalin-fixed paraffin-embedded tissue in 
routine diagnostics. Analysis of a validation cohort of 180 samples 
showed this approach to require significantly less input material and to 
be more reliable, robust, and cost-effective than conventional dideoxy 
sequencing. Subsequently, 2657 lung cancer patients were analyzed.
Results: We observed that comprehensive biomarker testing provided 
novel information in addition to histological diagnosis and clinical 
staging. In 2657 consecutively analyzed lung cancer samples, we 
identified driver mutations at the expected prevalence. Furthermore 
we found potentially targetable DDR2 mutations at a frequency of 
3% in both adenocarcinomas and squamous cell carcinomas.
Conclusion: Overall, our data demonstrate the utility of systematic 
sequencing analysis in a clinical routine setting and highlight the dra-
matic impact of such an approach on the availability of therapeutic 
strategies for the targeted treatment of individual cancer patients.
Key Words: Lung cancer, Next-generation sequencing, Routine 
diagnostic, Formalin-fixed, Amplicon.
(J Thorac Oncol. 2015;10: 1049–1057)
Lung cancer is histologically divided into small-cell lung car-cinomas and non–small-cell lung carcinomas (NSCLCs). 
NSCLC comprises approximately 85% of newly diagnosed 
lung cancers subclassified into adenocarcinoma (AD; ~50%), 
squamous cell carcinoma (SCC; ~30%), and large cell car-
cinoma (20%).1 Recently, treatment paradigms shifted from 
those based on mere morphology to one that incorporates 
actionable genomic alterations.2
The discovery of actionable mutations in the Epidermal 
Growth Factor Receptor (EGFR) gene and rearrangements 
of the Anaplastic Lymphoma Kinase (ALK) that are primarily 
found in AD patients have led to a remarkable improvement 
in overall survival of genetically selected patients.3,4 Also in 
SCC and small-cell lung carcinomas, several novel potential 
driver mutations are currently being evaluated as potential 
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actionable targets,5,6 for example, amplification of Fibroblast 
Growth Factor Receptor 1 (FGFR1).7–9 However, the transla-
tion of these scientific advances is currently hampered by the 
limited availability of genomic information on tumor material 
in clinical routine diagnostics.
Due to whole genome sequencing efforts in lung can-
cer,8,10–12 the number of newly identified potential driver muta-
tions,13 for example, Fibroblast Growth Factor 3, RET, and 
ROS,14 in lung cancer has increased steadily.15 The recently 
identified subgroups are small, comprising 0.5% to 3% of the 
lung cancer patients16,17 compared with the most frequently 
activated oncogene mutation in the V-Ki-ras2 Kirsten rat sar-
coma viral oncogene homolog18 gene found in 15% to 30% of 
NSCLC patients.19 Thus, routine molecular diagnostics for all 
actionable and potentially actionable driver mutations remains 
a growing challenge.
At present, mutation analysis of formalin-fixed paraf-
fin-embedded (FFPE) tumor tissue is mainly based on single 
sequential polymerase chain reaction (PCR) followed by con-
ventional dideoxy or Sanger sequencing (SS), which is both 
labor- and cost-intensive and limited by sensitivity and the 
amount of available DNA. Since we aimed to sequence the 
entire 3.2-kb coding region of Discoidin domain-containing 
receptor 2 (DDR2) to recruit patients into a clinical trial 
with Dasatinib entitled: “Trial of Dasatinib in Subjects With 
Advanced Cancers Harboring DDR2 Mutation or Inactivating 
B-RAF Mutation” (NCT01514864 clinicaltrials.gov), we 
opted to replace mutational analysis by SS with amplicon-
based massive parallel sequencing.20
With next-generation sequencing (NGS) benchtop 
devices becoming available, we aimed to reduce the time 
required for comprehensive molecular diagnostics and mini-
mize the amount of required FFPE-derived input DNA while at 
the same time increase the number of target regions analyzed.
MATERIALS AND METHODS
Sample Cohorts
Samples were analyzed as part of the standard diagnos-
tic procedures in agreement with guidelines, with approval of 
the local ethics committee (Ref Number: 10–242) and diag-
nosed based on the 2004 World Health Organization classifi-
cation of lung tumors21 and the International Multidisciplinary 
Classification of Lung Adenocarcinoma.22
For DNA extraction, tumor areas were marked on a 
hematoxylin and eosin-stained slide by a senior patholo-
gist. After deparaffination, tumor tissue was macrodissected 
from six unstained 10-μm sections and samples were lysed 
overnight with proteinase K at 37°C. Extraction was carried 
out automatically using a BioRobot M48 (Qiagen, Hilden, 
Germany) or a Maxwell 16 System (Promega, Madison, WI). 
Tumor content varied between 10% and 100%, with a mean 
value of 36.5% and a median of 30% (Fig. S3A, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A840), and 
we found a significant correlation between tumor content 
and allelic frequencies of the identified variants (Fig. S3B, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A840). Molecular diagnostics was performed at the accredited 
central molecular pathology laboratory using high-resolution 
melting prescreening and fragment length analysis as appro-
priate followed by SS.21,23
Ion AmpliSeq Custom DNA Panels 
and Library Preparation
DNA concentration was determined with the Qubit 
dsDNA HS Assay Kit (Life Technologies, Darmstadt, 
Germany) on the Qubit 2.0 Fluorometer. Up to 50 ng of FFPE 
DNA was amplified for 30 cycles with Ion AmpliSeq Custom 
DNA Panels (Life Technologies) covering 102 amplicons of 
12 different genes (Table S1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A839) split in two primer pools 
with the 5× Ion AmpliSeq HiFi Master Mix, which is part of 
Ion AmpliSeq DNA Library Kit 2.0. After treatment with the 
FuPa reagent, PCR products of both primer pools from the 
same patient were pooled. PCR products were purified with 
1.6× Agencourt AMPure XP beads (Beckman Coulter, Brea, 
CA) incubated for 5 minutes at room temperature, washed 
twice with 80% ethanol, and eluted in DNase/RNase free 
water. PCR products were incubated with NEXTflex DNA 
Adenylation Mix (Bioo Scientific, Austin, TX). NEXTflex 
DNA Barcode adapters (Bioo Scientific) were ligated to the 
fragments using Switch Solution and T4 DNA Ligase. Ligation 
products were cleaned up with 1.8× Agencourt AMPure XP 
beads incubated for 5 minutes at room temperature, washed 
twice with 80% ethanol, and eluted in DNase/RNase free 
water followed by size selection with 0.8× Agencourt AMPure 
XP beads incubated for 5 minutes at room temperature; the 
supernatant was collected and incubated with 0.2× Agencourt 
AMPure XP beads for 5 minutes at room temperature, washed 
twice with 80% ethanol, and eluted in DNase/RNase free 
water. The NEXTflex Primer Mix together with Platinum PCR 
SuperMix HiFi was used for the final PCR amplification with 
10 cycles and a final clean-up with 1× Agencourt AMPure XP 
beads for 5 minutes at room temperature, washed twice with 
80% ethanol, and eluted in DNase/RNase free water.
Sequencing Using the Illumina MiSeq Platform
Library concentration was determined with the Qubit 
dsDNA HS Assay Kit (Life Technologies) on the Qubit 2.0 
Fluorometer, which varied from 5 to 25 ng/μl. Libraries were 
diluted to 10 nM and pooled in equimolar amounts. Pooled 
libraries (5 ng/μl) were spiked with 5% PhiX DNA (Illumina, 
San Diego, CA) and sequenced paired end with the “MiSeq 
reagent Kit V2 (300-cycles)” (Illumina). FastQ files generated 
by the MiSeq Reporter were used as data output.
Generation of Variant Lists and 
Alignment of Raw Sequencing Reads
Briefly, after removing adapter sequences, raw reads 
(FastQ files) were aligned against reference NCBI build 37 
(human genome 19, hg19) and only against the chromosomal 
regions covered by our Custom Panel (CP) using Burrows 
Wheeler Alignment. Remaining unmapped reads were then 
realigned using BLAT24,25 to detect longer insertions or dele-
tions. After combining all alignments into a single BAM file, 
genomic variants were called using a modified version of 
our previously described method8 and adapted for targeted 
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sequencing. Variants were then imported into a FileMaker 
(FileMaker GmbH, Germany) database for further analysis, 
annotation, and reporting. BAM files were viewed in the 
Integrative Genomics Viewer (http://www.broadinstitute.
org/igv/).26,27
RESULTS
The Network Genomic Medicine Lung Cancer was 
founded at the Center for Integrated Oncology Cologne/Bonn 
by the Lung Cancer Group Cologne aiming at maximizing 
molecular testing in lung cancer to stratify approximately 
4000 lung cancer patients per annum for clinically approved 
targeted therapies or early phase clinical trials.2 FFPE sam-
ples of 2124 consecutive AD patients were received over a 
period of 21 months of which 1616 specimens were adequate 
for molecular analysis using the algorithm summarized in 
Figure S1A (Supplemental Digital Content 2, http://links.
lww.com/JTO/A840). Although 76.1% of samples with suf-
ficient tumor content to be successfully analyzed for EGFR 
and ALK aberrations, the amount of material was too small 
for completion of all our analysis in the extended diagnostic 
panel in more than 30% of the samples. In 42% of these AD 
patients, we identified at least one genomic lesion (Fig. S1B, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A840). The median turnaround time was 15 days and 21 days 
if ALK Fluorescence in situ hybridization was performed (Fig. 
S4, Supplemental Digital Content 2, http://links.lww.com/
JTO/A840).
Procedure of Amplicon Parallel 
Sequencing on the Illumina Platform
The AmpliSeq Cancer panel by Life Technologies seemed 
to be optimally suited to our requirements with the flexibility 
of the CP design. Initial test samples indicated that previously 
determined variants in routine diagnostic could be detected 
(Fig. S1A, Supplemental Digital Content 2, http://links.lww.
com/JTO/A840). To establish a specific lung cancer panel, 
we designed our own CP tailored to the genes of interest that 
show therapeutical relevance (Table S1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A839) for multiple ongo-
ing and future clinical studies (http://www.lungcancergroup.
de).28–33 We opted to sequence the multiplex PCR product on a 
MiSeq Benchtop sequencer (Illumina) (Fig. 1A, B). The modi-
fied library preparation protocol is depicted in Figure 1C.
Validation of the Ampliseq CP 
for Routine Diagnostics
Having shown that a combined approach of Ampliseq 
CPs Multiplex PCR with parallel sequencing on a MiSeq was 
feasible in terms of data quality, coverage of amplicons, and 
variant identification for a few test samples, we aimed to vali-
date this specific panel for our routine diagnostic workflow. 
One hundred eighty cases including lung, melanoma, colon, 
and gastrointestinal stromal tumor cancer samples previously 
analyzed in our routine diagnostic laboratory served as a vali-
dation cohort for the NGS pipeline, including samples with 
known mutations in EGFR, KRAS, BRAF, CTNNB1, TP53, 
NRAS, and ALK (Table 1; a complete list can be found in Table 
S2, Supplemental Digital Content 1, http://links.lww.com/
JTO/A839). For 169 cases, we asserted concordance of the 
SS and NGS analyses. Although eight samples had a concen-
tration below the input DNA concentration recommended by 
the AmpliSeq library preparation protocol (minimum of 10 ng 
per reaction), the previously determined mutations could be 
clearly detected (Sample No. 21, 70, 88, 101, 110, 114, 125, 
127). Approximately 30% of the FFPE samples in our institu-
tion do not fulfill the criteria for DNA quantity and quality. It 
should be mentioned that samples with low DNA content are 
prone to fixation artifacts and have a higher failure rate34,35 
(data not shown).
Initially, in 30 cases, the NGS analytic pipeline could not 
detect the previously determined mutation because the relevant 
A
B
C
FIGURE 1.  Schematic presentation of the library 
preparation. A and C, Genomic DNA (up to 50 ng) is 
amplified with the AmpliSeq Custom Panels. Primers 
are digested with FuPa, an “A” is added at the 3´ end 
to allow adapter ligation. After bead clean up and 
size selection, the successfully ligated products are 
amplified by PCR with a final bead clean up. Samples 
are quantified by Qubit, normalized to 10 nM, and 
pooled to be then sequenced on v2 MiSeq Cartridge. 
A table outline (A) and a cartoon (C) are depicted. B, 
Mutational analysis can be completed within 4 work-
ing days starting with the DNA extraction until data 
analysis. PCR, polymerase chain reaction.
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amplicons had a coverage of less than 100-fold. However, all 
these cases were successfully analyzed by resequencing with a 
higher DNA library input and/or lower number of samples per 
sequencing run, leading to a higher coverage per amplicon. 
Based on these observations, we determined a coverage of 
100 as cutoff value for evaluating every specific amplicon 
for further routine diagnostic procedure. Furthermore, the CP 
shows a diverse heterogeneity in terms of the representation of 
amplicons, with a coverage ranging from 100- to 10,000-fold 
(Fig. S5, Supplemental Digital Content 2, http://links.lww.
com/JTO/A840). We therefore consider the minimum cover-
age rather than the average covered to be a relevant quality 
parameter.
To check for robustness and reproducibility of our 
NGS pipeline, we performed inter- and intrareproducibility 
tests. We chose three samples with a previously determined 
mutation status and firstly conducted the library preparation 
setup in triplicates on two different days; secondly, a highly 
diluted sample; and thirdly, we used AmpliSeq Library Kit 
and Adenylation mix with different lot numbers under con-
stant conditions. All mutations could be confidently identified 
TABLE 1.  Summary of the Validation Procedure of 180 
Validation Cases
No. of Cases
Validation cohort 180
Concordant with SS 169
Discrepancies 11
Additional variant identified 75
Suboptimal input DNA 8
SS, Sanger sequencing.
A
D
B C
E
FIGURE 2.  Discrepancies between 
SS and NGS. A–C, Three of 11 cases 
with discrepancies between SS and 
NGS due to human errors in the 
mutation calling of the initial Sanger 
sequence are shown with 25 reads 
and two amino acids surrounding the 
affected amino acid are depicted. In 
addition, the allelic frequency (%) as 
well as coverage (x) is given. A, The 
peak representing the mutation from 
the electropherogram could not be 
assigned to its correct position for 
PIK3CA c.3140A>T p.H1047L because 
the primers are too close to the posi-
tion of the mutation. B, A clear C to A 
substitution in the Sanger sequence 
is visible but was misread as a G to 
C substitution leading to the wrong 
amino acid substitution, that is, 
c.34_35GG>CC p.G12L instead of 
c.34_35delinsTT p.G12F. C, In one 
patient, the correct base substitu-
tion was noted but the wrong amino 
acid substitution reported. D and 
E, Representative case in which a 
T790M resistance mutation was 
found in EGFR exon 20, which was 
not screened for by the SS pipeline 
(D). The pathogenic co-occurring 
mutation in the same sample in 
EGFR exon 21: c.2573T>G p.L858R is 
shown in (E). NGS, next-generation 
sequencing; SS, Sanger sequencing.
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in all samples with similar allelic frequencies. Furthermore, 
no additional variants were detected (Table S3, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A839).
Moreover, we performed NGS with three samples at 
two separate time points of extractions from the same block. 
Although DNA concentration differed between the two 
extractions and the resulting library concentration (Table S4, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A839), the sequencing results were congruent with respect to 
identifying the correct mutation.
Discrepancies between SS and NGS
We identified 11 cases with discrepancies between SS 
and NGS. Going back to the original Sanger electrophero-
grams, we found errors in the mutation calling of the initial 
Sanger sequence and not in the NGS sequences in 11 cases 
(Sample No. 66, 133, 158, 169, and 171–177) (Fig. 2A–C). 
Three mutations (Sample No. 178–180) could not be detected 
by NGS. Repeating the SS in two samples revealed a sample 
annotation error. The third sample involved a rare EGFR muta-
tion in Exon 18 (c.2125G>A p.E709K) that was called by the 
initial Sanger-based analysis. This mutation was considered to 
represent a fixation artifact resulting from deamination in the 
template DNA. Thus, we could identify all the mutations that 
were previously determined by SS and any discrepancies were 
unambiguously resolved. In the majority of cases this was due 
to human errors that occurred during initial Sanger analysis.
In 75 cases, we identified a total of 95 additional vari-
ants. Most of these occurred in the TP53 gene (more than 
50%) not previously tested for by SS. In three patients of our 
validation cohort, we observed a T790M mutation by NGS, 
not initially tested for in the SS pipeline, in addition to the 
activating EGFR mutations.36–38 The allele frequencies of the 
T790M mutations were 15.45%, 64.73%, and 77.49%, respec-
tively (Fig. 2D, E and data not shown).
Sample Preparation and Turnaround 
Time Is Reduced while Augmenting 
the Number of Targets
After successful validation, we implemented NGS in 
the routine diagnostic workflow and analyzed 4000 patients 
per annum by multiplexing 44 samples in equimolar concen-
trations, including one negative control per sequencing run 
(Fig. 1A). With an optimal cluster density of around 1000 K/
mm2, we are able to achieve a mean coverage of 4000× and a 
quality Q
30
 score of over 95% (Fig. 3A) and a minimal coverage 
of 500 in 99% of the amplicons (Fig. S5, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A840). The most critical 
amplicon was Phosphatase and tensin homolog (PTEN) exon 
9 (Table S1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A839), never reaching a coverage of higher than 50.
Starting from isolated DNA, we are in principle able to 
obtain data ready for evaluation within 4 days (Fig. 1B). In the 
context of a routine diagnostic setting with 15,000 single analy-
sis per year for various assays, the turnaround time was some-
what longer. In comparison to the SS approach, the overall time 
for sample preparation was reduced by 4.5 hours (Table 2), and 
the mean turnaround time was reduced from 12 days to 10 days 
for the entire NGS panel of 102 amplicons (Fig. 3B). However, 
it should be emphasized that the previous SS approach just cov-
ered four genes (KRAS, BRAF, EGFR, and PIK3CA), whereas 
NGS approach includes 102 amplicons spanning 14 genes. 
Additionally, as the integration of NGS is more practicable in 
A
B
FIGURE 3.  Multiplexing leads to reduced turn-
around time. A, The mean coverage for six runs on 
the MiSeq in a routine diagnostic is shown including 
the number of samples loaded (n), cluster density,49 
and the Quality30 score. B, The number of days to 
complete full analysis by SS (left panel) and NGS 
(right panel). n is the number of patients analyzed. 
NGS, next-generation sequencing; SS, Sanger 
sequencing.
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the course of routine diagnostic, we increased the number of 
samples for analysis by including patients diagnosed as SCC.
NGS in Routine Diagnostics Reveals a 
More Comprehensive Picture of Occurring 
Mutation Rates in ADs and SCCs
Since introducing NGS into the routine diagnos-
tic laboratory, we analyzed 1971 ADs and 686 SCCs and 
observed a different composition of mutation spectrum 
between AD and SCC (Fig. 4A). The most prevalent muta-
tions found in ADs were TP53 (35%), KRAS (26%), and 
EGFR (8%). The ranking of the most frequent mutations 
detected SCC is different: TP53 (57%), PTEN (8%), and 
PIK3CA (6%). In 13% of the samples of AD, and 12% of 
SCC, respectively, we could not detect any mutation by our 
CP and were reported as wildtype. In approximately 3% of 
all the cases, we were not able to obtain a diagnostic result 
due to low sample quality. TP53 mutations were a common 
additional genomic event in 35% of the ADs and 57% of 
the SCC samples. The distribution of mutations in SCC and 
AD were similar in the TP53 wild-type and mutant cases 
(Fig. 4B). TP53 mutations occurred in ADs most common 
together with KRAS mutations (46%) and in SCC together 
with PTEN mutations (31%).
In 2011, Hammerman et al39 reported somatic mutations 
in DDR2 at a frequency of 3.8% in cell lines and lung SCC 
samples, which could be confirmed in following reports.40,41 
We detected DDR2 mutations with a frequency of 3% in ADs 
(n = 67) and 3% in SCC (n = 25), suggesting that treatment 
with dasatinib may be of interest for study in clinical trials in 
both AD and SCC.
Additional Mutations Found by NGS 
Have a Positive Clinical Impact
We found two EGFR mutations in the validation cohort of 
180 cases and seven in a total of 315 samples that had been sent 
for molecular diagnostics all with an initial diagnosis of SCC 
by an external pathologist. Performing immunohistochemical 
staining for cytokeratin 7, thyroid transcription factor-1 (TTF1), 
p63/p40, and Napsin A42 (Fig. S7, Supplemental Digital Content 
2, http://links.lww.com/JTO/A840), we showed that three cases 
had been misdiagnosed as SCC but in fact were ADs. Only one 
sample was confirmed as a pure SCC with a rare EGFR exon 
19 deletion mutation (Fig. S8, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A840). Previously, this EGFR muta-
tion would not have been screened for in a SCC. However, 
because the NGS approach now screens for the complete muta-
tion spectrum in all NSCLC, the exact histopathological dif-
ferentiation of AD versus SCC in determining what molecular 
analysis needs to be performed is becoming less important.
NGS Pipeline Optimizations
Even though NGS replaced SS in our routine diagnostic 
laboratory, several changes needed to be made to the original 
workflow based on the experiences gained from the first 1000 
samples analyzed. The following adaptations were imple-
mented: up to 44 samples are multiplexed during a Miseq run 
including one negative control. We avoid using the adapters 
containing the same barcode in consecutive runs. Furthermore, 
we determine the number of reads harboring barcodes not 
used in the library preparation to detect contaminations.
The mutation and coverage files generated by the bioin-
formatic pipeline are imported into our evaluation and annota-
tion database developed in-house. Variants are always checked 
visually in the Integrative Genomics Viewer. Annotations of 
every new occurring variant are stored in a central annotation 
database after intense literature research, which is updated on 
a regular basis.
A major issue of analyzing FFPE material is the occur-
rence of fixation artifacts that are purine substitutions. When 
a sample shows an increased and unlikely number of G>A or 
C>T or vice versa transition rate, that is, usually more than 15 
variants per sample, only those having an allelic frequency of 
over 10% are reported.34,43
DISCUSSION
The identification of novel targetable driver mutations 
in cancer makes accurate and rapid molecular diagnostics a 
requirement for most cancer patients.8,10,12 Until recently, detec-
tion of somatic mutations in routine FFPE samples relied on sin-
gle, often sequentially performed assays for each potential driver 
event. This is time consuming, cost and labor intensive, and is 
TABLE 2.  Opposing the Laboratory Turnaround Time for 48 
Samples by AmpliSeq Custom Panel Sequenced on the MiSeq 
Versus Former Routine Workflow Including Hands-On Time
Time 
Duration
Hands-On 
Time
Sanger and HRM (for 48 
samples; min 4 to max 10 
analysis)
  Quantification NanoDrop and 
Agarose
30 min 30 min
  BRAF and KRAS HRM 6 hr 2 hr
Sanger  
(15 samples)
20 hr 2 hr
  EGFR FA and Sanger  
(32 samples)
18.5 hr 1.5 hr
  PIK3CA HRM 4 hr 2 hr
Sanger  
(5 samples)
18 hr 1 hr
  Data analysis 4 hr 4 hr
Total 71 hr 13 hr
NGS (for 48 samples;  
102 targets)
  Quantification Qubit 30 min 30 min
  Multiplex PCR 4 hr 1.5 hr
  Library preparation 7 hr 4.5 hr
  Quantification,  
normalization, pooling
1 hr 1 hr
  MiSeq 26 hr 30 min
  Data analysis 28 hr 4 hr
Total 66.5 hr 12 hr
HRM, high-resolution melting; FA, fragment length analysis; NGS, next-generation 
sequencing; PCR, polymerase chain reaction.
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limited by the availability of small amounts of tumor material, 
particularly in lung cancer where often only small biopsies or 
cytologies can be obtained.35 To overcome these limitations, 
we implemented a multiplex PCR for clinically relevant driver 
mutations followed by parallel sequencing. The Ion AmpliSeq 
Multiplex PCR was ideally suited for use in routine diagnostic 
because the content is highly customizable and optimized for 
applications on FFPE. In combinations with the higher sequenc-
ing accuracy of the Illumina sequencing platform, we estab-
lished a highly reliable clinical diagnostic test.44–46
A
B
FIGURE 4.  NGS in routine diagnostics reveals expected mutation frequencies for EGFR, KRAS, and BRAF as well as an equal 
mutation rate for DDR2 in ADs and SCC. A and B, One thousand nine hundred seventy-one consecutive ADs and 686 SCCs 
were analyzed by NGS, which detected driver mutations in 87% of the samples with frequencies depicted here. DDR2 muta-
tions were found with a frequency of 3% both in ADs and SCCs. C and D, Thirty-five percent of the ADs and 57% of the SCCs 
samples harbored TP53 mutations. All TP53 mutated cases and the frequency of co-occurring driver mutations are depicted. 
ADs, adenocarcinomas; SCC, squamous cell carcinoma.
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This approach required some modifications to the 
library preparation protocol, namely after end-repair of the 
PCR products, an adenosine overhang was generated to allow 
for efficient adapter ligation.
By analyzing a broad array of different driver mutation 
in lung cancer in parallel, we were able to gather a comprehen-
sive overview of the mutations distribution in our local patient 
cohort (Fig. 4). These data are consistent with previously pub-
lished data.11,33,47
Previously, it was not always possible to screen patients 
for rare mutations by SS due to lack of material and workload 
constraints. Using a multiplex PCR approach to analyze all 
NSCLC patients for a board array of targetable driver muta-
tions, we identified several patients with the initial diagnosis of 
an SCC who harbored actionable EGFR mutations that other-
wise would not have been evaluated. Retrospective analysis of 
this cohort revealed a false histological classification as SCC 
instead of AD in three patients at the time of initial diagnosis. 
In addition, we also identified one SCC with a rare targetable 
EGFR mutation (Fig. 3D, E; Figs. S7 and S8, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A840).
These findings imply that comprehensive testing of all 
NSCLC patients reduces the need for extensive immunhis-
tochemical subtyping of small poorly differentiated tumor 
specimens.
A further challenge in the application of precision medi-
cine in cancer patients is the occurrence of primary and sec-
ondary resistance.48 Thus, NGS-based diagnostic platforms 
will have broad implication for the detection of resistance 
mechanisms already at time of the initial molecular analysis 
and may guide novel studies to overcome primary and second-
ary resistance mechanisms. In this study, we demonstrate that 
our multiplex PCR and NGS-based platform is sensitive and 
robust and requires less input material, thus reducing the num-
ber of patients in whom input material is limiting. At the same 
time, the turnaround time was significantly reduced and the 
number of target regions was increased by more than 10-fold 
compared with the previous SS approach. Furthermore, this 
alternative approach minimized the difficulty of mutation call-
ing inherent to SS. Thus, NGS technologies, complemented 
with a customized bioinformatics pipeline optimized for a 
high-throughput diagnostic setting, provide a powerful tool to 
screen lung cancer patient in routine diagnostics.
CONCLUSION
In conclusion, NGS-based diagnostic approaches have 
now been developed into robust, reliable, fast, and cost-effec-
tive assays that will increasingly replace single sequential 
PCR-based or SS-based approaches.
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